Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 1/20 | 0.59 |
| ▸ | PPARG | P37231 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | MAP2 | P11137 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6922317 | 0.93 | PPARG (0.66) | TSPOPPARGKDM4EALDH1A1TACR1 | |
| SCHEMBL7238028 | 0.92 | TSPO (0.58) | TSPOPPARGKDM4EALDH1A1CYP1A2 | |
| SCHEMBL7242328 | 0.92 | PPARG (0.61) | TSPOPPARGKDM4EALDH1A1CYP1A2 | |
| SCHEMBL7233621 | 0.92 | TSPO (0.57) | TSPOPPARGKDM4EALDH1A1CYP1A2 | |
| SCHEMBL7790372 | 0.90 | PPARG (0.53) | TSPOPPARGKDM4EALDH1A1CYP1A2 | |
| SCHEMBL7241655 | 0.90 | PPARG (0.50) | TSPOPPARGKDM4EALDH1A1CYP1A2 | |
| SCHEMBL7242930 | 0.89 | PPARG (0.50) | TSPOPPARGKDM4EALDH1A1CYP1A2 | |
| SCHEMBL7234310 | 0.86 | PPARG (0.60) | TSPOPPARGKDM4EALDH1A1CYP1A2 | |
| SCHEMBL7233759 | 0.85 | CXCR2 (0.52) | TSPOPPARGKDM4EALDH1A1CYP1A2 | |
| SCHEMBL7233766 | 0.85 | PPARG (0.58) | TSPOPPARGKDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605633-B1 | Such as 5-Bromo-2-phenyl-1H-indole-3-butanoic acid | FOURNIER INDUSTRIE ET SANTE (FR) | 2003-08-12 | — | — | US | disclosed |
| US-6518273-B1 | 2-aryl indole derivative as antagonists of tachykinins | MERCK SHARP & DOHME LTD. | 2003-02-11 | — | — | US | disclosed |
| US-6476045-B2 | INDOLE AND AZAINDOLE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS, AND IN PARTICULAR AS NEUROKININ-1 RECEPTOR ANTAGONIST | MERCK SHARP & DOHME LTD. (GB) | 2002-11-05 | — | — | US | disclosed |
| US-20020022624-A1 | Azaindole derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2002-02-21 | — | — | US | disclosed |
| US-20010039286-A1 | 2-aryl indole derivatives and their use as therapeutic agents | DINNELL KEVIN (GB) | 2001-11-08 | — | — | US | disclosed |
| WO-2000051984-A1 | 2-ARYL INDOLE DERIVATIVES AS ANTAGONISTS OF TACHYKININS | MERCK SHARP & DOHME LIMITED (GB) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039286-A1 | 2-aryl indole derivatives and their use as therapeutic agents | IDO1, IDO2, CNR2 | TSPO 2379/4885PPARG 568/4885KDM4E 2526/4885 |
| US-20020022624-A1 | Azaindole derivatives and their use as therapeutic agents | HTR2B, HNMT, HTR1B | TSPO 2610/4885PPARG 289/4885KDM4E 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.